Cargando…
Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients
BACKGROUND: Prostate cancer is a heterogeneous malignancy with outcome difficult to predict. Currently, there is an urgent need to identify novel biomarkers that can accurately predict patient outcome and improve the treatment strategy. The aim of this study was to investigate the methylation status...
Autores principales: | Deng, Qiu-Kui, Lei, Yong-Gang, Lin, Ying-Li, Ma, Jian-Guo, Li, Wen-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758335/ https://www.ncbi.nlm.nih.gov/pubmed/26881880 http://dx.doi.org/10.12659/MSM.897179 |
Ejemplares similares
-
Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy
por: Lin, Ying-Li, et al.
Publicado: (2015) -
Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer
por: Lin, Ying-Li, et al.
Publicado: (2017) -
Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma
por: Lin, Ying-Li, et al.
Publicado: (2017) -
Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer
por: Lin, Ying-Li, et al.
Publicado: (2014) -
Adjuvant Treatment for Protocadherin 19 (PCDH19) Syndrome
por: Moncayo, Juan A, et al.
Publicado: (2022)